Provectus presents update on PV-10 drug at European Cancer Congress

Knoxville-based Provectus Pharmaceuticals, Inc., presented  detailed findings from the Phase 2 trial of its PV-10 drug yesterday at the “European Cancer Congress 2013” in Amsterdam, The Netherlands. For more information, read the company’s news release.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.